

# Xuan Gao

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7395196/publications.pdf>

Version: 2024-02-01

16  
papers

231  
citations

1478505

6  
h-index

1125743

13  
g-index

16  
all docs

16  
docs citations

16  
times ranked

283  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Circulating tumor DNA analyses predict progressive disease and indicate trastuzumab-resistant mechanism in advanced gastric cancer. <i>EBioMedicine</i> , 2019, 43, 261-269.   | 6.1 | 68        |
| 2  | Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma. <i>Oncologist</i> , 2021, 26, e1110-e1124.   | 3.7 | 56        |
| 3  | CCND1 Amplification Contributes to Immunosuppression and Is Associated With a Poor Prognosis to Immune Checkpoint Inhibitors in Solid Tumors. <i>Frontiers in Immunology</i> , 2020, 11, 1620.                           | 4.8 | 44        |
| 4  | Immune checkpoint inhibitors for brain metastases in non-small-cell lung cancer: from rationale to clinical application. <i>Immunotherapy</i> , 2021, 13, 1031-1051.   | 2.0 | 14        |
| 5  | RBM10 Deficiency Is Associated With Increased Immune Activity in Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 677826.   | 2.8 | 7         |
| 6  | Associations of HER2 Mutation With Immune-Related Features and Immunotherapy Outcomes in Solid Tumors. <i>Frontiers in Immunology</i> , 2022, 13, 799988.  | 4.8 | 7         |
| 7  | Time-spatial analysis of T cell receptor repertoire in esophageal squamous cell carcinoma patients treated with combined radiotherapy and PD-1 blockade. <i>OncolImmunology</i> , 2022, 11, 2025668.                     | 4.6 | 6         |
| 8  | Comprehensive Comparative Molecular Characterization of Young and Old Lung Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 806845.   | 2.8 | 6         |
| 9  | CCND1 Amplification Profiling Identifies a Subtype of Melanoma Associated With Poor Survival and an Immunosuppressive Tumor Microenvironment. <i>Frontiers in Immunology</i> , 0, 13, .                                  | 4.8 | 6         |
| 10 | Immune Subtypes in LUAD Identify Novel Tumor Microenvironment Profiles With Prognostic and Therapeutic Implications. <i>Frontiers in Immunology</i> , 2022, 13, .  | 4.8 | 5         |
| 11 | The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 834142.  | 4.8 | 4         |
| 12 | A high homologous recombination deficiency score is associated with poor survival and a non-inflamed tumor microenvironment in head and neck squamous cell carcinoma patients. <i>Oral Oncology</i> , 2022, 128, 105860. | 1.5 | 4         |
| 13 | The prevalence of HLA*LOH in Chinese pan-cancer patients and genomic features of patients harboring HLA*LOH. <i>Human Mutation</i> , 2021, 42, 1254-1264.  | 2.5 | 2         |
| 14 | An Immune-Related Prognostic Signature for Predicting Clinical Outcomes and Immune Landscape in IDH-Mutant Lower-Grade Gliomas. <i>Journal of Oncology</i> , 2021, 2021, 1-19.   | 1.3 | 2         |
| 15 | Genomic clonal evolution correlated with phenotype and prognosis in gastric cancer. <i>Clinical and Translational Medicine</i> , 2022, 12, e799.   | 4.0 | 0         |
| 16 | Multi-omics analysis of locally advanced esophageal cell squamous carcinoma treated with radio-chemotherapy. <i>Journal of Clinical Oncology</i> , 2022, 40, e16106-e16106.  | 1.6 | 0         |